Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Adcetris / brentuximab vedotin for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma as of May 2025

MARA Rating Company December 16, 2025

Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma as of February 2021

MARA Rating Company December 16, 2025

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over as of June 2023

MARA Rating Company December 16, 2025

Brigatinib / alunbrig for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor as of January 2021

MARA Rating Company December 16, 2025

Brolucizumab / beovu for treating wet age-related macular degeneration as of February 2021

MARA Rating Company December 16, 2025

Brolucizumab / beovu for treating visual impairment due to diabetic macular oedema as of August 2022

MARA Rating Company December 16, 2025

Jorveza / budesonide for inducing remission of eosinophilic oesophagitis as of June 2021

MARA Rating Company December 16, 2025

Bulevirtide for treating chronic hepatitis D as of June 2023

MARA Rating Company December 16, 2025

Atezolizumab for untreated metastatic non-small-cell lung cancer (NSCLC) as of June 2021

MARA Rating Company December 16, 2025

Atezolizumab / tecentriq for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable as of October 2021

MARA Rating Company December 16, 2025